Abstract
This review of the July 2013 to December 2014 publications on cytokines and monoclonal antibodies covers bone morphogenic proteins, colony-stimulating factors, interferons, interleukins, tumor necrosis factor alfa, adalimumab, certolizumab, etanercept, golimumab, infliximab, abciximab, alemtuzumab, bevacizumab, cetuximab, daclizumab, natalizumab, ranibizumab, rituximab, tocilizumab and trastuzumab.
| Original language | English |
|---|---|
| Title of host publication | A worldwide yearly survey of new data in adverse drug reactions, 2015 |
| Publisher | Elsevier |
| Pages | 461-470 |
| Number of pages | 10 |
| Volume | 37 |
| ISBN (Print) | 9780444635259 |
| DOIs | |
| State | Published - 2015 |
Publication series
| Name | Side Effects of Drugs Annual |
|---|---|
| Volume | 37 |
| ISSN (Print) | 03786080 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology
- Pharmacology (medical)
- Drug guides
Cite this
Drugs That Act on the Immune System. Cytokines and Monoclonal Antibodies. / Jha, Lokesh K.; Mukherjee, Sandeep.
A worldwide yearly survey of new data in adverse drug reactions, 2015. Vol. 37 Elsevier, 2015. p. 461-470 (Side Effects of Drugs Annual; Vol. 37).Research output: Chapter in Book/Report/Conference proceeding › Conference contribution
}
TY - GEN
T1 - Drugs That Act on the Immune System. Cytokines and Monoclonal Antibodies
AU - Jha, Lokesh K.
AU - Mukherjee, Sandeep
PY - 2015
Y1 - 2015
N2 - This review of the July 2013 to December 2014 publications on cytokines and monoclonal antibodies covers bone morphogenic proteins, colony-stimulating factors, interferons, interleukins, tumor necrosis factor alfa, adalimumab, certolizumab, etanercept, golimumab, infliximab, abciximab, alemtuzumab, bevacizumab, cetuximab, daclizumab, natalizumab, ranibizumab, rituximab, tocilizumab and trastuzumab.
AB - This review of the July 2013 to December 2014 publications on cytokines and monoclonal antibodies covers bone morphogenic proteins, colony-stimulating factors, interferons, interleukins, tumor necrosis factor alfa, adalimumab, certolizumab, etanercept, golimumab, infliximab, abciximab, alemtuzumab, bevacizumab, cetuximab, daclizumab, natalizumab, ranibizumab, rituximab, tocilizumab and trastuzumab.
UR - http://www.scopus.com/inward/record.url?scp=84978975420&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978975420&partnerID=8YFLogxK
U2 - 10.1016/bs.seda.2015.08.006
DO - 10.1016/bs.seda.2015.08.006
M3 - Conference contribution
SN - 9780444635259
VL - 37
T3 - Side Effects of Drugs Annual
SP - 461
EP - 470
BT - A worldwide yearly survey of new data in adverse drug reactions, 2015
PB - Elsevier
ER -